Feb 16, 2016 · Our pharmacological studies confirmed that 2-DG, an inhibitor of HK2, inhibited human and mouse lung cancer cell growth through inducing cell apoptosis and autophagy. HK2 is a promising treatment target for NSCLC with Kras activating and p53 function loss.

Sep 16, 2013 · To directly target the glycolytic pathway in CD8 + T cells, we used the Hk2 inhibitor 2DG. Previous reports have demonstrated that cell proliferation was blocked by high concentrations of 2DG (50 mM) (36).

Hexokinase 2 (HK2), an enzyme of the sugar kinase family, plays a dual role in glucose metabolism and mediating cancer cell apoptosis, making it an attractive target for cancer therapy. While positive HK2 expression usually promotes cancer cells ...

The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.

Sep 1, 2022 · Hexokinase 2 (HK2) is the rate-limiting enzyme catalyzing the first step of glycolysis, and is often overexpressed in most cancer cells. Thus, targeting HK2 appears to be a promising anticancer therapy.

These results indicate that HK2-mediated glycolysis plays a crucial role in the increased tolerance of ALK⁺ NSCLC cells to crizotinib. 2DG may sensitize ALK⁺ NSCLC to crizotinib via suppression of HK2-mediated glycolysis and the AKT/mTOR signaling pathway.

Nov 2, 2021 · HK2 expression was effectively suppressed by 2DG alone, or in combination with crizotinib, rendering HK2 susceptible to 2DG treatment. In conclusion, HK2 may play a central role in 2DG targeting glycolysis for inhibition of ALK + NSCLC cell proliferation.

Jan 1, 2023 · In this study, we examined the role of HK2 inhibition by 2-DG in regulating the cVIM and the interplay between autophagy and apoptosis in FLSs. We further investigated a possible mechanism by which HK2 inhibition modulates autophagy through the HK2/mTOR signaling pathway in FLSs.

Our pharmacological studies confirmed that 2-DG, an inhibitor of HK2, inhibited human and mouse lung cancer cell growth through inducing cell apoptosis and autophagy. HK2 is a promising treatment target for NSCLC with Kras activating and p53 function loss. Keywords: NSCLC, HK2, Kras, 2-DG, Apoptosis.

Feb 7, 2025 · Knockdown of TWIST1 or HK2 enhanced the inhibitory effects of 2DG on cell migration and invasion. Treatment with Elesclomol-Cu and 2DG significantly reduced the expression of the cuproptosis-related factor FDX1 with no impact on other cell death factors.